e-Therapeutics plc Exercise of Options and Issue of Equity (7757A)
January 24 2024 - 5:04AM
UK Regulatory
TIDMETX
RNS Number : 7757A
e-Therapeutics plc
24 January 2024
e-therapeutics plc
("e-therapeutics" or the "Company")
Exercise of Options and Issue of Equity
London, UK, 24 January 2024 - e-therapeutics plc (AIM: ETX;
OTCQX; ETXPF), a company integrating computational power and
biological data to discover life-transforming RNAi medicines,
announces that it has allotted 400,000 new ordinary shares of 0.1p
each in the Company (the "New Ordinary Shares") following the
exercise of 400,000 employee share options at an exercise price of
0.1p per share.
Application has been made to AIM for the admission of the New
Ordinary Shares to trading on AIM ("Admission") and Admission is
expected to occur at 8:00 a.m. on or around 31 January 2024. The
New Ordinary Shares will rank pari passu in all respects with the
Company's existing ordinary shares in issue.
Following Admission, the total number of ordinary shares in the
Company with voting rights in issue will be 584,335,487. This
figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
Company under the Financial Conduct Authority's Disclosure and
Transparency Rules.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation.
For further information, please contact:
Enquiries:
e-therapeutics plc
Ali Mortazavi, CEO Tel: +44 (0)20 4551
Timothy Bretherton, CFO 8888
www.etherapeutics.co.uk
------------------------------------------------- -------------------------
SP Angel Corporate Finance LLP Tel: +44(0)20 3470
0470
Nominated Adviser and Broker
Matthew Johnson/Harry Davies-Ball (Corporate
Finance)
Vadim Alexandre/Rob Rees (Corporate Broking)
------------------------------------------------- -------------------------
About e-therapeutics plc
e-therapeutics plc ("ETX") integrates computational power and
biology information to discover life-transforming RNAi medicines.
The Company's technology uses computation to capture and model
human biology, identify novel targets, and develop RNAi medicines
against those targets that can be rapidly progressed to the
clinic.
ETX's proprietary HepNet(TM) platform enables the generation and
analysis of biological network models, providing a novel and
mechanistic approach to drug discovery. This approach explicitly
considers the true complexity of biology to make more reliable
predictions from large complex data sets and ETX's proprietary
hepatocyte knowledgebase - the world's most comprehensive and
integrated hepatocyte-centric data resource. The Company generates,
prioritises, and tests millions of hypotheses in silico to identify
better therapeutic targets with higher confidence.
GalOmic(TM), ETX's proprietary RNAi platform, enables targeted
delivery to hepatocytes in the liver and the specific silencing of
novel disease-associated genes, identified by HepNet(TM). The focus
on hepatocytes offers the opportunity to tackle a wide variety of
diseases. The liver is a highly metabolically active organ which
performs a key role in many biological processes and vital
functions crucial for human health. ETX's GalOmic(TM) constructs
have demonstrated compelling in vivo performance in terms of depth
of gene silencing and duration of action.
The Company is progressing a pipeline of first-in-class RNAi
candidates across a variety of therapeutic areas with high unmet
need, including preclinical programs in cardiometabolic and
metabolic diseases, haemophilia, and other undisclosed indications.
ETX has also partnered with biopharma companies such as Novo
Nordisk, Galapagos NV and iTeos Therapeutics using its
computational network biology approach across a diverse range of
drug discovery projects.
The Company is based in London, UK and listed on the Alternative
Investment Market of the London Stock Exchange ("AIM"), with ticker
symbol ETX.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEGZGZMGDFGDZM
(END) Dow Jones Newswires
January 24, 2024 05:04 ET (10:04 GMT)
E-therapeutics (LSE:ETX)
Historical Stock Chart
From Nov 2024 to Dec 2024
E-therapeutics (LSE:ETX)
Historical Stock Chart
From Dec 2023 to Dec 2024
